1,755 filings
Page 13 of 88
6-K
n3nzesxum96e5b8
1 Nov 17
Teva Announces Completion of PARAGARD® Divestiture to CooperSurgical
12:00am
SC 13G
h20ariip1pfpshnyz
31 Oct 17
Mesoblast LTD
12:00am
6-K
mp0y7hgkmpj5jm
31 Oct 17
Teva Wins Generic Uceris®patent Trial
12:00am
SC 13G/A
yknqlnmp1a44 nsx4m
31 Oct 17
Mesoblast LTD
12:00am
6-K
xb0p1 qhymu
30 Oct 17
Live Filing
12:00am
6-K
s3dm1978 l0iue6oqu3q
26 Oct 17
Presentations Span Teva’s Respiratory Portfolio – including Rescue, Maintenance Inhalers and Biologic Asthma Treatment
12:00am
6-K
irory8
19 Oct 17
Teva to Highlight New Data in Multiple Sclerosis at Joint ECTRIMS – ACTRIMS Congress in Paris
12:00am
6-K
d5nh84 vts0y9n3wvrv3
17 Oct 17
Teva Announces Submission of Biologics License Application for Fremanezumab to the U.S. FDA
12:00am
6-K
q8afqo6ww 9qy1
10 Oct 17
Live Filing
12:00am
6-K
9q88499m 2i
4 Oct 17
Teva Comments on Anticipated At-Risk U.S. Launch of Generic Glatiramer Acetate 40mg/mL and Launch of Generic Glatiramer Acetate 20mg/mL
12:00am
6-K
q6ww hidt6z7
25 Sep 17
Teva Announces Reintroduction of Generic Depo-provera® In the United States
12:00am
6-K
kexe39 x9g79n
25 Sep 17
Live Filing
12:00am
6-K
mzh bgp3zi0yb4
19 Sep 17
Teva and Nuvelution Pharma Partner to Accelerate Development of AUSTEDO® (deutetrabenazine) Tabletsfor Use in Tourette Syndrome in the United States
12:00am
6-K
o90lmzmeyfvlbz
19 Sep 17
Amendment to Senior Unsecured Revolving Credit Agreement
12:00am
6-K
ve2uwy562fp sg1254ur
18 Sep 17
New initiative creates scalable solutions to improve care of patients with multiple chronic conditions
12:00am
6-K
kr6nwnlmemoc777dlf62
18 Sep 17
Teva Announces Sale of Remaining Assets in Specialty Global Women’s Health Portfolio for $1.38 Billion
12:00am
6-K
ayepce
14 Sep 17
Teva to Present Data for AUSTEDO® (deutetrabenazine) Tablets and Other Research at the 2017 Psych Congress
12:00am
6-K
ryr7tjgmhokgv2uom
12 Sep 17
Live Filing
12:00am
6-K
rd52g ylc
11 Sep 17
Teva Announces Sale of PARAGARD® (intrauterine copper contraceptive) to CooperSurgical
12:00am
6-K
fqreh5zvbkpdznbf
11 Sep 17
Teva Names Kåre Schultz as President and Chief Executive Officer
12:00am